Restriction of Dietary AGEs to Prevent Diabetes in Overweight Individuals
Primary Purpose
Advanced Glycation Endproducts, AGEs, Diet
Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Diet low or high in advanced glycation endproducts
Sponsored by
About this trial
This is an interventional basic science trial for Advanced Glycation Endproducts
Eligibility Criteria
Inclusion Criteria:
- Abdominal obesity: waist circumference for men ≥ 102 cm, and for women ≥ 88 cm.
- Aged 18 years and older
- Caucasian (because of skin fluorescence and capillary microscopy measurements)
Exclusion Criteria:
- Diabetes (i.e. using anti-diabetic medication, fasting glucose >7.0 mmol/L, HbA1c >6.5%).
- Active or history of cardiovascular disease (e.g. stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)
- Hyperlipidemia (defined as serum total cholesterol > 8 mmol/L or TG > 4 mmol/L)
- Lipid lowering medication (e.g. statins)
- Use of medication known to influence glucose metabolism, vascular function and/or lipid metabolism (e.g. statins, glucocorticosteroids, NSAID's)
- Inability to stop antihypertensive medication for 13 weeks. Exclusion of higher grade hypertension (> 179 mmHg SBP and/or > 109 mmHg DBP) in order not to expose subjects to unnecessary risks)
- Pulmonary or inflammatory disease
- Kidney failure or electrolyte disorders
- Pregnancy or lactation
- No change in use of oral anticonceptiva or IUD (12 weeks prior of during the intervention)
- Known allergic reaction to ultrasound contrast-agent
- Smoking (active or cessation <1 year prior to screening date).
- High alcohol usage (>4 U/day) or drug abuse
- Use of dietary supplements or an investigation product within the previous month
- Significant food allergies/intolerance
- Vegetarianism
- Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the intervention.
- Participation in another biomedical trial during the past 30 days.
Sites / Locations
- Maastricht University
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Other
Arm Label
Low AGE diet
High AGE diet
Arm Description
Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.
Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.
Outcomes
Primary Outcome Measures
Insulin sensitivity
Assessed by hyperinsulinaemic-euglycaemic clamp
Secondary Outcome Measures
Microvascular function
Assessed by contrast-enhanced ultrasound (CEUS) in skeletal muscle
Full Information
NCT ID
NCT03866343
First Posted
March 6, 2019
Last Updated
March 5, 2021
Sponsor
Maastricht University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT03866343
Brief Title
Restriction of Dietary AGEs to Prevent Diabetes in Overweight Individuals
Official Title
Restriction of Dietary AGEs to Prevent Diabetes in Overweight Individuals: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
September 7, 2018 (Actual)
Primary Completion Date
March 3, 2021 (Actual)
Study Completion Date
March 3, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Current efforts to arrest the epidemic of type 2 diabetes mellitus (T2DM) have had limited success. Thus there is an urgent need for effective approaches to prevent the development of T2DM. It is widely accepted that the current epidemic is driven by an increase in global food abundance and reduced food quality, making changes in diet a key determinant of the T2DM epidemic. Dietary factors can affect cardio-metabolic health; among these factors, advanced glycation end-products (AGEs) in food are potential risk factors for insulin resistance and T2DM.
AGEs are a heterogeneous group of unavoidable stable bioactive compounds. Endogenous formation of AGEs is a continuous naturally occurring process, and is the result of normal metabolism. However, increased formation of AGEs occurs during ageing and under hyperglycaemic conditions. AGEs are implicated in the development of diabetes and vascular complications.
Over the past several decades, methods of food processing have changed and meals now contain excess fat and sugar and are most susceptible for the formation of AGEs. In addition, AGEs in food are highly desirable due to their profound effect on shelf life, sterility, flavour, colour, and thus food consumption. Hence, a substantial portion of AGEs are derived from exogenous sources, particularly food. These exogenous AGEs are potential risk factors for insulin resistance and the development of T2DM. The investigators recently found that dietary AGEs represent a significant source of circulating AGEs, and have similar pathogenic properties compared to their endogenous counterparts including the development of insulin resistance and T2DM. Taken together, dietary AGEs are proposed to play a pivotal role in the development and progression of T2DM and its complications. Reduction of dietary intake of AGEs may therefore be an alternative strategy to reduce the risk of vascular disease and insulin resistance. The investigators therefore hypothesize that dietary restriction of AGEs in overweight individuals improves insulin sensitivity, β-cell function, and vascular function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Glycation Endproducts, AGEs, Diet, Insulin Sensitivity/Resistance, Beta-cell Function, Vascular Function
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
82 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low AGE diet
Arm Type
Active Comparator
Arm Description
Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.
Arm Title
High AGE diet
Arm Type
Other
Arm Description
Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.
Intervention Type
Other
Intervention Name(s)
Diet low or high in advanced glycation endproducts
Intervention Description
All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
Primary Outcome Measure Information:
Title
Insulin sensitivity
Description
Assessed by hyperinsulinaemic-euglycaemic clamp
Time Frame
Difference after 4 weeks of intervention
Secondary Outcome Measure Information:
Title
Microvascular function
Description
Assessed by contrast-enhanced ultrasound (CEUS) in skeletal muscle
Time Frame
Difference after 4 weeks of intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Abdominal obesity: waist circumference for men ≥ 102 cm, and for women ≥ 88 cm.
Aged 18 years and older
Caucasian (because of skin fluorescence and capillary microscopy measurements)
Exclusion Criteria:
Diabetes (i.e. using anti-diabetic medication, fasting glucose >7.0 mmol/L, HbA1c >6.5%).
Active or history of cardiovascular disease (e.g. stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)
Hyperlipidemia (defined as serum total cholesterol > 8 mmol/L or TG > 4 mmol/L)
Lipid lowering medication (e.g. statins)
Use of medication known to influence glucose metabolism, vascular function and/or lipid metabolism (e.g. statins, glucocorticosteroids, NSAID's)
Inability to stop antihypertensive medication for 13 weeks. Exclusion of higher grade hypertension (> 179 mmHg SBP and/or > 109 mmHg DBP) in order not to expose subjects to unnecessary risks)
Pulmonary or inflammatory disease
Kidney failure or electrolyte disorders
Pregnancy or lactation
No change in use of oral anticonceptiva or IUD (12 weeks prior of during the intervention)
Known allergic reaction to ultrasound contrast-agent
Smoking (active or cessation <1 year prior to screening date).
High alcohol usage (>4 U/day) or drug abuse
Use of dietary supplements or an investigation product within the previous month
Significant food allergies/intolerance
Vegetarianism
Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the intervention.
Participation in another biomedical trial during the past 30 days.
Facility Information:
Facility Name
Maastricht University
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6226
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
35133989
Citation
Linkens AM, Houben AJ, Niessen PM, Wijckmans NE, de Goei EE, Van den Eynde MD, Scheijen JL, van den Waarenburg MP, Mari A, Berendschot TT, Streese L, Hanssen H, van Dongen MC, van Gool CC, Stehouwer CD, Eussen SJ, Schalkwijk CG. A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals. JCI Insight. 2022 Mar 22;7(6):e156950. doi: 10.1172/jci.insight.156950.
Results Reference
derived
Learn more about this trial
Restriction of Dietary AGEs to Prevent Diabetes in Overweight Individuals
We'll reach out to this number within 24 hrs